



Transcriptional Studies on a *Streptomyces clavuligerus oppA2* Deletion Mutant: *N*-Acetylglycyl-Clavaminic Acid Is an Intermediate of Clavulanic Acid Biosynthesis

R. Álvarez-Álvarez,^a A. Rodríguez-García,^b Y. Martínez-Burgo,^a J. F. Martín,^a P. Liras^a

^aDepartment of Molecular Biology, Faculty of Biological and Environmental Sciences, University of León, León, Spain

^bInstitute of Biotechnology of León, INBIOTEC, León, Spain

ABSTRACT The *oppA2* gene encodes an oligopeptide-binding protein similar to the periplasmic substrate-binding proteins of the ABC transport systems. However, *oppA2* is an orphan gene, not included in an ABC operon. This gene is located in the clavulanic acid (CA) gene cluster of *Streptomyces clavuligerus* and is essential for CA production. A transcriptomic study of the *oppA2*-null mutant *S. clavuligerus* $\Delta oppA2::aac$ showed changes in the expression levels of 233 genes from those in the parental strain. These include genes for ABC transport systems, secreted proteins, peptidases, and proteases. Expression of the clavulanic acid, clavam, and cephamycin C biosynthesis gene clusters was not significantly affected in the *oppA2* deletion mutant. The genes for holomycin biosynthesis were upregulated 2-fold on average, and the level of upregulation increased to 43-fold in a double mutant lacking *oppA2* and the pSCL4 plasmid. Strains in which *oppA2* was mutated secreted into the culture the compound *N*-acetylglycyl-clavaminic acid (AGCA), a putative intermediate of CA biosynthesis. A culture broth containing AGCA, or AGCA purified by liquid chromatography-mass spectrometry (LC-MS), was added to the cultures of various non-CA-producing mutants. Mutants blocked in the early steps of the pathway restored CA production, whereas mutants altered in late steps did not, establishing that AGCA is a late intermediate of the biosynthetic pathway, which is released from the cells when the oligopeptide-binding protein OppA2 is not available.

IMPORTANCE The *oppa2* gene encodes an oligopeptide permease essential for the production of clavulanic acid. A transcriptomic analysis of *S. clavuligerus* $\Delta oppA2::aac$ in comparison to the parental strain *S. clavuligerus* ATCC 27064 is reported. The lack of OppA2 results in different expression of 233 genes, including genes for proteases and genes for transport systems. The expression of the clavulanic acid genes in the *oppA2* mutant is not significantly affected, but the genes for holomycin biosynthesis are strongly upregulated, in agreement with the higher holomycin production by this strain. The *oppA2*-mutant is known to release *N*-acetylglycyl-clavaminic acid to the broth. Cosynthesis assays using non-clavulanic acid-producing mutants showed that the addition of pure *N*-acetylglycyl-clavaminic acid to mutants in which clavulanic acid formation was blocked resulted in the recovery of clavulanic acid production, but only in mutants blocked in the early steps of the pathway. This suggests that *N*-acetylglycyl-clavaminic acid is a previously unknown late intermediate of the clavulanic acid pathway.

KEYWORDS oligopeptide permeases, ATP binding cassettes, *Streptomyces clavuligerus*, *oppA2* gene, clavulanic acid, transcriptional analysis

Received 12 July 2018 Accepted 23 August 2018

Accepted manuscript posted online 7 September 2018

Citation Álvarez-Álvarez R, Rodríguez-García A, Martínez-Burgo Y, Martín JF, Liras P. 2018. Transcriptional studies on a *Streptomyces clavuligerus oppA2* deletion mutant: *N*-acetylglycyl-clavaminic acid is an intermediate of clavulanic acid biosynthesis. *Appl Environ Microbiol* 84:e01701-18. <https://doi.org/10.1128/AEM.01701-18>.

Editor Rebecca E. Parales, University of California, Davis

Copyright © 2018 American Society for Microbiology. All Rights Reserved.

Address correspondence to P. Liras, paloma.liras@unileon.es.

ATP-binding transport cassettes (ABC) are ubiquitous systems typically consisting of (i) a periplasmic substrate-binding protein, OppA, with high substrate specificity in Gram-negative bacteria, (ii) two hydrophobic integral membrane proteins, OppB and OppC, containing at least six membrane-spanning domains, with their N- and C-terminal ends located in the cytoplasm, and (iii) two ATP binding cytoplasmic proteins, OppD and OppE, which provide the energy to transport the substrate by ATP hydrolysis (1). In Gram-positive bacteria, the OppA subunit is located on the cell surfaces and is anchored in the membrane by a lipophilic acyl residue (2). Some of these ABC-type systems are involved in peptide transport and play important roles in Gram-positive bacteria, such as cell wall recycling (3), signaling at the onset of *Bacillus subtilis* sporulation (4), and aerial mycelium formation in *Streptomyces* species (5, 6). In *Streptomyces coelicolor*, the BldK transporter imports an extracellular signaling molecule that governs aerial mycelium formation through the lantibiotic-like peptide SapB (5, 7, 8). A similar system is present in *Streptomyces griseus* (9). Genes for ABC transport systems are normally clustered and coordinately expressed, as occurs in *Salmonella enterica* serovar Typhimurium (10) or in the *S. coelicolor* BldKABCDE cluster (5). However, isolated genes encoding OppA subunits are occasionally found in bacteria without the cognate genes encoding the OppBCDE subunits.

Streptomyces clavuligerus produces the β -lactamase inhibitor clavulanic acid (CA). This compound is formed by the condensation of arginine and glyceraldehyde-3-phosphate by the N^2 -(2-carboxyethyl)-arginine synthase (CeaS2), encoded by *ceaS2* (also named *pyc* [11]). Cyclization of N^2 -(2-carboxyethyl)-arginine by the β -lactam synthase (BlS), encoded by *bls2*, results in deoxyguanidine-proclavaminic acid formation. This compound is transformed through several enzymatic steps into (3S,5S)-clavaminic acid, *N*-glycylclavaminic acid (NGCA), (3*R*,5*R*)-clavalddehyde, and finally (3*R*,5*R*)-clavulanic acid (12) (Fig. 1). Most of the genes encoding enzymes for the steps leading to NGCA (*ceaS2*, *bls2*, *pah2*, *cas2*, and *gcaS*) and the gene involved in the final step of clavulanic acid biosynthesis (*car*) have been characterized; however, the functions of several genes essential for CA formation (*oppA1*, *cyp*, *orf12*, *orf13*, *orf14*, *oppA2*, *orf16*) and located in the CA cluster are still unknown.

Two genes encoding orphan oligopeptide-binding proteins, *oppA1* and *oppA2*, are located in the *S. clavuligerus* clavulanic acid gene cluster (13, 14) (Fig. 1A). These orphan OppA proteins are likely to be substrate-binding proteins rather than components of a complete ABC transport system, since the *oppB*-to-*oppE* genes, forming the corresponding ABC transport system, are not located close to *oppA1* or *oppA2*. However, genes for complete ABC transporter systems are present elsewhere in the *S. clavuligerus* genome. OppA1 and OppA2 are both essential for CA production but appear to have different substrate-binding specificities and functions, since they cannot replace each other when expressed in the other gene-disrupted mutant (15).

Crystal structures of the oligopeptide-binding proteins complexed with tripeptide and tetrapeptide ligands have been obtained (16). The crystal structure of *S. clavuligerus* OppA2 binds di- or tripeptides containing arginine, a CA precursor, and arginine-containing complex molecules (17). Since all the *oppA2* mutants studied secrete the arginine-derived peptide *N*-acetylglycyl-clavaminic acid (AGCA) (14, 15), we hypothesize that this compound might be a ligand for OppA2 and an intermediate of the CA pathway. Therefore, it was important to know whether the lack of CA formation was due to an effect of OppA2 on the transcription of the clavulanic acid biosynthesis genes or to a role of OppA2 in the cellular localization of AGCA and its conversion to clavulanic acid.

The characterization of the OppA2 function was hampered by the recent finding that the mutant *S. clavuligerus oppA2::aph* (15), now renamed *S. clavuligerus oppA2::aph* pSCL^{low}, contains lower copy numbers of plasmids pSCL2 and pSCL4 in the mycelium than the wild-type *S. clavuligerus* strain ATCC 27064 (18). Plasmid pSCL4 (1.8 Mb) is an important reservoir of secondary metabolite gene clusters, whereas pSCL1 (11 kb) and pSCL2 (120 kb) are not so well described (19). Therefore, a new strain with *oppA2* deleted, but carrying standard copy numbers of plasmids pSCL1, pSCL2 and pSCL4, was




FIG 1 Clavulanic acid gene cluster and pathway. (A) Clavulanic acid gene cluster. Filled arrows represent genes encoding enzymes of the pathway and the transcriptional cluster activator, *ClrA*. Open arrows represent genes with unclear functions. Note that some genes with unknown functions—*oppA1*, *cyp-fd*, *orf12*, and *oppA2*—are essential for clavulanic acid biosynthesis. The locations of genes *oppA1* and *oppA2* are indicated above the diagram. (B) Clavulanic acid biosynthesis pathway. The names and chemical structures of the intermediate compounds are given. The enzymes and genes involved in each step are shown.

constructed (18) and is designated *S. clavuligerus* $\Delta oppA2::aac$ (referred to as *S. clavuligerus* $\Delta oppA2::aac$ pSCL4⁺ in reference 18). Both *S. clavuligerus* *oppA2::aph* pSCL^{low} and *S. clavuligerus* $\Delta oppA2::aac$ overproduce the yellow antibiotic holomycin, which is encoded by the holomycin gene cluster (20, 21).

This work presents a transcriptomic study of *S. clavuligerus* $\Delta oppA2::aac$ to elucidate the effect of the *oppA2* mutation on the expression of the CA biosynthesis genes and to prove, through cosynthesis assays, that AGCA is an intermediate in the clavulanic acid pathway.

RESULTS

Characteristics of the *oppA2* gene and its encoded protein. The *oppA2* gene, located in the clavulanic acid gene cluster, encodes an oligopeptide-binding orphan protein similar to those of ABC systems. *OppA2* has 562 amino acids and possesses 75% and 81% identity with the homologous *OppA2* proteins from *Saccharomonospora viridis* (WP_015787617.1, Svir_33430) and *Streptomyces flavogriseus* (WP_014152681.1, Sfla_0541), encoded by genes located in the clavulanic acid clusters of these actinomycetes (22). The amino acid identity between *OppA2* and *OppA1* (SCLAV_4192), also located in the *S. clavuligerus* clavulanic acid gene cluster, is 49%, whereas the amino acid identity decreases to 29 to 41% when *OppA2* is compared with other oligopeptide transporters, such as those encoded by SCLAV_3976 (*BldKB*), SCLAV_4035, and SCLAV_4406, all of them genes located in complete ABC transporter clusters in the *S.*

clavuligerus genome, suggesting that OppA2 is a protein specific for clavulanic acid biosynthesis.

Transcriptomic analysis of *S. clavuligerus* $\Delta oppA2::aac$ compared to its parental strain, *S. clavuligerus* ATCC 27064. A comparative transcriptomic analysis of *S. clavuligerus* $\Delta oppA2::aac$ and the parental strain *S. clavuligerus* ATCC 27064 was carried out to determine the effect of OppA2 on gene transcription. Three percent of the genes analyzed showed statistically significant differences in their expression (233 genes of the 7,589 present in the microarray). Those genes with M_c values (binary log values of the differential transcription between the mutant and the wild-type strain) greater than 2 or less than -2 for at least one of the sampling times and with statistically significant changes in expression levels (Benjamini-Hochberg [BH] false-discovery rate-corrected P value, <0.05) were considered in the study. The differentially expressed genes were classified as follows: (i) 28 genes encoding transport component systems, secreted proteins, peptidases, or proteases, (ii) 10 regulatory genes, (iii) 45 genes located in secondary metabolite gene clusters, (iv) 79 genes with diverse functions, and (v) 71 genes encoding hypothetical proteins (see Table S1 in the supplemental material).

Genes encoding transport systems, secreted proteins, proteases, or peptidases whose expression is affected in the *oppA2* mutant. The lack of the orphan peptide-binding protein OppA2 upregulates 12 genes encoding components for transport systems (Table 1) in the *S. clavuligerus* $\Delta oppA2::aac$ mutant at the three sampling times used and downregulates SCLAV_0928, a divalent metal ion/citrate complex secondary transporter. Six of the upregulated genes encode members of ABC transport systems. The clustered genes SCLAV_2953 and SCLAV_2954, coding for a peptide transport system, showed the highest upregulation (5.1- and 5.8-fold, respectively). Likewise, the changes in the expression of genes SCLAV_1661 to -1663, coding for an ABC transport system, increased steadily in the *oppA2* mutant strain, as high as 9-fold over expression in the control strain (Fig. 2). A group of 15 genes differentially transcribed in the *oppA2* mutant encode secreted proteins, proteases, or peptidases (Table 1). All these genes were up- or downregulated in *S. clavuligerus* $\Delta oppA2::aac$ at least 4-fold at some sampling time. Three of these genes (SCLAV_3505, SCLAV_p1084, and SCLAV_p1085) encode peptidases of the S1/S6 family. The last two genes (as well as SCLAV_p1086 and SCLAV_p1087, encoding hypothetical proteins) are located upstream of *res2*, in the clavulanic acid paralogous gene cluster, and showed 32- and 26-fold-higher expression, respectively, in the *oppA2* mutant than in the wild-type strain in the early-exponential phase (Fig. 3A). The role of these peptidases in the CA paralogous gene cluster is unknown, but their strong upregulation suggests a linkage between OppA2 and the CA paralogous gene cluster. A strong upregulatory transcriptional effect was observed for a gene encoding the ATP-dependent Clp protease subunit (SCLAV_0526 [Fig. 3B]) and the adjacent SCLAV_0527 gene (not shown), especially at stationary phase (40-fold increase), but no significant effect was observed for genes encoding other components of the Clp complex (SCLAV_1784 to SCLAV_1786). Also upregulated were the genes encoding the extracellular neutral protease (SCLAV_4112 [Fig. 3C]) and the subtilisin-like protease (SCLAV_p0750), which were expressed at some sampling times at levels 10.1- and 6.4-fold higher than those in the wild-type strain, respectively (Table 1). Coregulated expression of independent substrate-binding proteins and secreted proteins has been described previously (23).

Transcription of antibiotic biosynthesis gene clusters in the strain lacking OppA2. *S. clavuligerus* *oppA2*-null mutants do not produce clavulanic acid, behave like the wild-type strain in relation to cephamycin C production, and produce large amounts of holomycin (14, 15). The expression of the genes encoding these antibiotics was analyzed in the wild-type strain and the mutant *S. clavuligerus* $\Delta oppA2::aac$.

Clavulanic acid and clavam gene clusters. The lack of OppA2 completely blocked clavulanic acid production in the mutant *S. clavuligerus* $\Delta oppA2::aac$ (Fig. 4A, left). The transcription of *oppA2* was null in the *oppA2* deletion mutant (Table 2); however, the expression of the upstream gene (*orf16*) that is cotranscribed with *oppA2* (24) was not significantly affected. Similar expression of *orf14* in the wild-type strain and the *oppA2*

TABLE 1 Genes differentially transcribed in *S. clavuligerus* Δ oppA2::aac and *S. clavuligerus* ATCC 27064

Gene and category	Product	M_c^a			BH false-discovery rate-corrected <i>P</i> value			Fold change ^b		
		22.5 h	46.5 h	60 h	22.5 h	46.5 h	60 h	22.5 h	46.5 h	60 h
Transport systems										
SCLAV_0398	Cobalamin/Fe ³⁺ -siderophore transport system permease	0.76	2.33	0.38	5.33E-01	3.88E-03	7.79E-01	1.70	5.04	1.30
SCLAV_0928	Divalent metal ion/citrate complex secondary transporter	-0.05	0.05	-2.13	9.87E-01	9.73E-01	4.47E-02	1.04	1.04	4.37
SCLAV_1661	ABC transporter integral membrane protein	1.71	2.35	3.15	3.10E-03	2.19E-04	3.50E-06	3.28	5.09	8.86
SCLAV_1662	ABC transporter ATP-binding protein	1.49	2.50	3.19	2.03E-03	9.62E-06	1.47E-07	2.81	5.64	9.16
SCLAV_1663	ABC transport system transmembrane protein	1.31	2.40	3.15	2.63E-03	4.26E-06	7.21E-08	2.47	5.28	8.89
SCLAV_2323	Putative permease of the major facilitator superfamily	0.24	2.06	0.17	9.17E-01	1.04E-02	9.25E-01	1.18	4.17	1.12
SCLAV_2953	ABC transporter-related protein	2.34	1.31	1.14	1.23E-05	4.16E-03	1.24E-02	5.07	2.48	2.21
SCLAV_2954	ABC transporter-related protein	2.53	1.03	0.49	1.23E-05	2.70E-02	4.27E-01	5.78	2.05	1.40
SCLAV_3442	Integral membrane transport protein	0.40	2.63	0.38	8.56E-01	6.77E-03	8.32E-01	1.32	6.19	1.30
SCLAV_4876	Major facilitator superfamily transporter	0.49	2.53	0.10	7.75E-01	3.43E-03	9.61E-01	1.40	5.79	1.07
SCLAV_5031	Putative glutamate ABC transporter permease	0.96	2.29	0.14	4.90E-01	1.24E-02	9.48E-01	1.95	4.89	1.10
SCLAV_5717	Putative cation efflux system protein	0.88	2.25	0.26	5.09E-01	9.39E-03	8.78E-01	1.83	4.77	1.20
SCLAV_p1593	Ferric enterobactin transport system; permease FepG	0.34	2.22	0.82	8.68E-01	9.39E-03	4.65E-01	1.27	4.67	1.76
Proteases and peptidases										
SCLAV_0526	ATP-dependent Clp protease, proteolytic subunit	2.30	2.80	5.34	8.67E-03	1.88E-03	5.45E-07	4.92	6.96	40.45
SCLAV_3418	Protease inhibitor protein	-2.05	-0.83	-3.37	1.28E-01	5.28E-01	6.45E-03	4.13	1.78	10.36
SCLAV_4112	Extracellular small neutral protease	2.82	3.34	1.92	1.28E-02	3.37E-03	9.85E-02	7.07	10.10	3.78
SCLAV_5431	Subtilisin-like serine protease	0.01	2.07	1.07	9.98E-01	3.36E-02	3.99E-01	1.01	4.19	2.10
SCLAV_p0399	Chymotrypsin-2-like protease	-0.90	-2.16	-0.09	5.18E-01	1.47E-02	9.67E-01	1.87	4.48	1.06
SCLAV_p0750	Subtilisin-like protease	2.68	1.86	1.37	6.30E-03	4.34E-02	2.03E-01	6.41	3.64	2.59
SCLAV_2331	Peptidase S58 DmpA	0.43	2.31	-0.42	8.29E-01	9.86E-03	7.93E-01	1.35	4.97	1.33
SCLAV_2381	Peptidase	0.68	2.26	0.32	6.08E-01	4.89E-03	8.22E-01	1.60	4.79	1.25
SCLAV_3505	Peptidases of the S1/S6 family, chymotrypsin/Hap	1.52	1.67	2.33	2.87E-01	1.18E-01	4.16E-02	2.86	3.18	5.04
SCLAV_5212	Glutamyl endopeptidase II	-2.37	-0.76	0.92	1.71E-03	3.01E-01	2.88E-01	5.18	1.70	1.90
SCLAV_p1084	Peptidases of the S1/S6 family	4.99	0.54	0.59	1.84E-04	7.36E-01	7.84E-01	31.82	1.45	1.51
SCLAV_p1085	Peptidases of the S1/S6 family	4.69	0.80	0.46	5.24E-04	5.84E-01	8.49E-01	25.80	1.74	1.38
Secreted proteins										
SCLAV_1071	Putative secreted protein	-1.59	-3.71	-0.37	1.73E-01	5.01E-04	8.42E-01	3.01	13.07	1.29
SCLAV_p0575	Putative secreted protein	2.09	0.83	0.03	3.13E-02	3.85E-01	9.88E-01	4.26	1.77	1.02
SCLAV_p1196	Secreted protein	-2.30	-4.41	-2.85	1.15E-01	1.48E-03	3.15E-02	4.93	21.29	7.21

^aThe transcription values in *S. clavuligerus* ATCC 27064 are taken as 1.0.

^bShaded values correspond to genes that were downregulated at the indicated times.

mutant (Table 2) was also observed, ruling out the possibility that *oppA2* deletion exerted a polar effect on *orf14* expression; this was also confirmed by complementation experiments of the *oppA2* mutation (see below). The BH false-discovery rate-corrected *P* values of <0.05 for the 18 genes of the CA cluster indicate that there were no significant transcriptional differences due to the lack of OppA2 (Table 2). In summary, all the evidence indicates that the OppA2 protein does not exert transcriptional control on the CA gene cluster, although the mutant did not produce CA (Fig. 4A, left).

No significant differences in the transcription level of the chromosomal clavam gene cluster (SCLAV_2922 to SCLAV_2929) or of the pSCL4-located clavulanic acid paralogous gene cluster (SCLAV_p1070 to SCLAV_p1082) were observed (Table 2), although the expression of SCLAV_p1079, encoding the transcriptional regulator Cvm7P, increased 4.1-fold at the exponential-growth phase.

Cephameycin C gene cluster. The differences in the expression of 16 genes (*pcbR* to *pbp74*; SCLAV_4198 to SCLAV_4215) of the cephamycin gene cluster between the two strains were quite low; on average, 1.5- and 1.3-fold increases in transcription at the early-exponential and exponential phases, and 2.3-fold decreases at the stationary-growth phase, were observed (Table 2). The most affected genes were those coding for isopenicillin N epimerase, deacetylcephalosporin C hydroxylase, and C-7 cephalosporin hydroxylase (*cefD*, *cefE*, *cmcl*), which were downregulated 5- to 7-fold at the stationary-




FIG 2 Transcriptomic pattern of the SCLAV_1660-to-SCLAV_1664 gene cluster. (A) Organization of the genes in the cluster. (B) Transcriptomic levels (M_g values) of the genes SCLAV_1660 to SCLAV_1664 in *S. clavuligerus* ATCC 27064 (open circles) and *S. clavuligerus* $\Delta oppA2::aac$ (filled circles). Vertical lines show standard deviations.

growth phase. This slight effect of OppA2 on the expression of the cephamycin C genes agrees with the similar levels of cephamycin C production by the *oppA2* mutant and the wild-type strain that were observed in this work (average, 80% production with respect to the wild-type strain at the different sampling times), and by other authors (14, 25).

The lack of OppA2 strongly upregulates the holomycin gene cluster. Holomycin is not detectable in cultures of the wild-type strain, *S. clavuligerus* ATCC 27064, whereas *S. clavuligerus* $\Delta oppA2::aac$, as also reported for other *oppA2*-null mutants, produced large amounts of holomycin (15) (see Fig. S1 in the supplemental material). This also occurs in strains carrying *oppA2* but lacking plasmid pSCL4 (18, 26, 27). In this work, the expression of the genes for holomycin biosynthesis (*hlm*) in *S. clavuligerus* ATCC 27064 and *S. clavuligerus* $\Delta oppA2::aac$, with *oppA2* deleted, is compared; in addition, the *S. clavuligerus* pSCL4⁻ mutant, which carries a normal *oppA2* gene but lacks plasmid pSCL4, and the double mutant *S. clavuligerus* $\Delta oppA2::aac$ pSCL4⁻, which lacks both






FIG 3 Transcriptomic patterns of genes encoding peptidases and proteases in *S. clavuligerus* ATCC 27064 (open symbols) and *S. clavuligerus* $\Delta oppA2::aac$ (filled symbols). (A) Transcriptomic levels (M_g values) of SCLAV_p1084 (circles) and SCLAV_p1085 (squares), encoding type S1/S6 peptidases. (B) M_g values of SCLAV_0526, encoding the ATP-dependent Clp protease. (C) M_g values of SCLAV_4112, encoding an extracellular neutral protease. Vertical lines show standard deviations.

A. Antibiotic Production



B. AGCA imidazole derivatized HPLC Analyses



C. AGCA Mass Spectra




FIG 4 Effects of the *oppA2* complementation in *S. clavuligerus oppA2::acc*[pAV11-*oppA2*]. (A) Production of antibiotics by *S. clavuligerus* ATCC 27064 (open circles), *S. clavuligerus* $\Delta oppA2::aac$ (filled circles), *S. clavuligerus oppA2::aac[pAV11-*oppA2*] (triangles), and *S. clavuligerus* $\Delta oppA2::aac$ [pAV11] (squares). (Left) Production of clavulanic acid; (right) production of holomycin. (B) HPLC analysis of AGCA formation by the distinct strains. The name of each strain is given beside the HPLC pattern. The AGCA peak is indicated by an arrow. (C) Mass spectra of imidazole-derivatized AGCA (left) and of underivatized AGCA (right).*

oppA2 and plasmid pSCL4, were included in the study (Table 3). All the *hlm* genes were upregulated in the three mutant strains. The upregulation was higher at the exponential phase of growth, coinciding with the holomycin production phase, and also at the stationary phase in the double mutant (Fig. S1).

TABLE 2 Transcriptomic data for genes of the clavulanic acid, cephamycin C, clavam, and clavulanic acid paralogous gene clusters in *S. clavuligerus* Δ oppA2::acc versus *S. clavuligerus* ATCC 27064

Gene cluster and gene	Gene function ^a	M_c^b			BH false-discovery rate-corrected <i>P</i> value			Fold change ^c		
		22.5 h	46.5 h	60 h	22.5 h	46.5 h	60 h	22.5 h	46.5 h	60 h
Clavulanic acid gene cluster										
<i>ceaS2</i>	Carboxyethylarginine synthase	-0.16	0.14	-1.19	9.17E-01	8.70E-01	4.02E-02	0.90	1.10	0.44
<i>bls2</i>	Carboxyethyl-arginine β -lactam synthase	0.02	0.19	-1.01	9.91E-01	8.20E-01	9.73E-02	1.01	1.14	0.50
<i>pah2</i>	Proclavamate amidinohydrolase	0.14	0.48	-1.46	9.48E-01	5.56E-01	4.78E-02	1.10	1.39	0.36
<i>cas2</i>	Clavamate synthase 2	-0.08	0.29	-1.35	9.70E-01	6.97E-01	3.07E-02	0.95	1.23	0.39
<i>oat2</i>	Ornithine <i>N</i> -acetyltransferase	0.44	-0.03	0.09	6.22E-01	9.69E-01	9.37E-01	1.36	0.98	1.07
<i>oppA1</i>	Substrate-binding protein	-0.13	0.17	-1.38	9.50E-01	8.72E-01	5.28E-02	0.91	1.13	0.38
<i>claR</i>	Transcriptional activator ClaR	0.57	0.01	-1.16	7.06E-01	9.97E-01	1.96E-01	1.49	1.00	0.45
<i>car</i>	Clavalddehyde dehydrogenase	-0.24	-0.07	-1.23	9.15E-01	9.58E-01	2.22E-01	0.85	0.95	0.43
<i>cyp</i>	Cytochrome P450	0.16	0.08	-1.89	9.31E-01	9.44E-01	7.41E-03	1.12	1.05	0.27
<i>fd</i>	Ferredoxin	0.10	0.23	-1.82	9.54E-01	7.77E-01	4.98E-03	1.07	1.17	0.28
<i>orf12</i>	Putative transpeptidase, β -lactamase-like	-0.23	0.30	-1.11	8.96E-01	7.43E-01	1.53E-01	0.85	1.23	0.46
<i>orf13</i>	Putative acetylserine/cysteine exporter	0.85	-0.06	0.10	2.85E-01	9.50E-01	9.48E-01	1.81	0.96	1.07
<i>orf14</i>	GNAT-like	-1.36	-1.19	-0.82	6.69E-02	6.76E-02	3.14E-01	0.39	0.44	0.57
<i>oppA2</i>	Solute binding protein	-7.46	-7.33	-5.57	1.18E-04	1.82E-04	4.02E-03	0.01	0.01	0.02
<i>orf16</i>	NAT-like protein	0.01	0.30	-1.93	9.98E-01	7.84E-01	2.14E-02	1.01	1.23	0.26
<i>gcas</i>	<i>N</i> -Glycyl-clavaminic acid synthetase	-0.11	-0.05	-2.23	9.62E-01	9.70E-01	6.62E-03	0.93	0.97	0.21
<i>pbpA</i>	Penicillin-binding protein (PBP)	0.45	0.11	-0.05	2.67E-01	7.96E-01	9.52E-01	1.37	1.08	0.97
<i>pbp2</i>	Penicillin-binding protein	0.15	-0.07	-0.22	6.33E-01	7.84E-01	3.22E-01	1.11	0.95	0.86
Avg (except oppA2)		-0.38	-0.36	-1.34				1.01	1.00	0.5
Cephamycin C gene cluster										
<i>pcbR</i>	Penicillin-binding protein	0.10	0.22	0.00	8.70E-01	4.26E-01	9.99E-01	1.07	1.16	1.00
<i>pcbC</i>	Isopenicillin N synthetase	0.17	0.10	-1.79	9.35E-01	9.37E-01	1.88E-02	1.12	1.07	0.29
<i>pcbAB</i>	<i>N</i> - δ -Aminoacyl-L-cysteine-L-valine synthetase	0.57	0.11	-2.81	7.39E-01	9.38E-01	3.85E-03	1.48	1.08	0.14
<i>lat</i>	L-Lysine- ϵ -aminotransferase	0.28	0.42	-2.56	9.25E-01	7.65E-01	1.74E-02	1.21	1.34	0.17
<i>blp</i>	β -Lactamase inhibitory protein-like	1.51	1.21	0.21	1.57E-01	1.72E-01	9.15E-01	2.85	2.31	1.16
<i>orf10</i>	Secreted protein	0.53	-0.13	-0.83	4.51E-01	8.62E-01	1.14E-01	1.45	0.91	0.56
<i>ccaR</i>	Positive regulator	1.04	0.36	-0.13	1.07E-02	3.79E-01	8.64E-01	2.05	1.28	0.91
<i>cmcH</i>	3'-OH-methylcephem- <i>O</i> -carbamoyl transferase	0.37	0.22	-2.45	8.49E-01	8.63E-01	5.67E-03	1.29	1.16	0.18
<i>ceff</i>	Deacetoxycephalosporin C hydroxylase	0.63	0.83	-2.43	7.92E-01	5.10E-01	3.80E-02	1.55	1.78	0.19
<i>cmC</i>	Protein of the methoxylation system	0.57	0.66	-2.88	8.19E-01	6.20E-01	1.38E-02	1.49	1.59	0.14
<i>cmI</i>	Cephalosporin hydroxylase, CmI	0.59	0.61	-2.23	7.84E-01	6.17E-01	3.57E-02	1.51	1.52	0.21
<i>cefD</i>	Isopenicillin N epimerase	0.60	0.55	-2.63	8.14E-01	7.09E-01	2.91E-02	1.52	1.47	0.16
<i>cefE</i>	Deacetoxycephalosporin C synthetase	0.81	0.63	-1.79	6.73E-01	6.09E-01	1.11E-01	1.75	1.54	0.29
<i>pcd</i>	Aldehyde dehydrogenase	0.38	0.22	-1.46	7.06E-01	7.49E-01	8.07E-03	1.30	1.17	0.36
<i>cmcT</i>	Fourteen-domain transmembrane protein	0.56	0.66	-0.94	4.63E-01	1.92E-01	9.00E-02	1.48	1.58	0.52
<i>pbp74</i>	Penicillin-binding protein	-0.05	-0.01	-0.38	9.55E-01	9.79E-01	2.91E-01	0.97	0.99	0.77
<i>bla</i>	β -Lactamase	-0.02	0.17	0.46	9.90E-01	7.84E-01	4.38E-01	0.99	1.12	1.37
Avg		0.51	0.40	-1.45				1.48	1.36	0.5
Clavam gene cluster										
<i>cvm9</i>	DNA-binding protein	0.01	-0.09	-0.38	9.94E-01	8.70E-01	3.79E-01	1.01	0.94	0.77
<i>cvm6</i>	PP-dependent aminotransferase-like	-0.87	-0.28	0.06	3.84E-01	7.76E-01	9.71E-01	0.55	0.82	1.04
<i>cvm5</i>	F420-dependent methylenetetrahydromethanopterin reductase	0.36	1.45	0.06	8.45E-01	5.80E-02	9.75E-01	1.28	2.73	1.04
<i>cvm4</i>	Alpha/beta hydrolase	-0.49	-0.27	-0.59	3.81E-01	5.61E-01	2.06E-01	0.71	0.83	0.67
<i>cas1</i>	Clavamate synthase 1	0.07	2.03	-0.01	9.82E-01	3.76E-02	9.96E-01	1.05	4.10	0.99
<i>cvm1</i>	Aldo/keto reductase	0.46	-0.44	-0.10	3.02E-01	1.98E-01	8.93E-01	1.38	0.74	0.94
<i>cvm2</i>	Hypothetical protein	-0.32	-0.77	-0.98	8.37E-01	2.57E-01	2.07E-01	0.80	0.59	0.51
<i>cvm3</i>	Flavin reductase-like protein	-0.61	0.98	0.30	6.91E-01	2.29E-01	8.51E-01	0.65	1.98	1.23
<i>cvm7</i>	AfsR-family transcriptional regulator	0.11	0.68	0.79	9.32E-01	1.19E-01	1.02E-01	1.08	1.60	1.73
<i>cvm11</i>	Putative translocator	0.05	-0.22	0.18	9.62E-01	5.70E-01	7.55E-01	1.03	0.86	1.13
<i>cvm12</i>	Putative transcriptional regulator	0.20	0.17	0.22	8.08E-01	7.18E-01	7.22E-01	1.15	1.13	1.16
<i>cvm13</i>	β -Aspartyl-peptidase	-1.22	-0.28	0.22	1.77E-02	6.40E-01	8.08E-01	0.43	0.83	1.16
<i>cvmH</i>	LanU-like protein	-0.11	0.49	-0.74	9.50E-01	4.15E-01	2.58E-01	0.93	1.40	0.60
<i>cvmP</i>	Arginine deiminase-like protein	0.56	0.84	0.99	4.03E-01	6.96E-02	4.62E-02	1.47	1.79	1.98
<i>cvmG</i>	Hypothetical protein	0.07	0.19	0.28	9.55E-01	7.15E-01	6.64E-01	1.05	1.14	1.21
Avg		-0.12	0.30	0.02				0.97	1.43	1.08
Clavulanic acid paralogous gene cluster										
SCLAV_p1069	Dehydratase	-0.04	-0.07	0.26	9.86E-01	9.49E-01	8.44E-01	0.97	0.95	1.20
SCLAV_p1070	Aminotransferase	0.26	1.71	0.37	9.21E-01	5.72E-02	8.30E-01	1.19	3.26	1.29
SCLAV_p1071	YjgF-type family regulator	-0.04	0.18	-0.42	9.81E-01	8.18E-01	5.96E-01	0.97	1.13	0.75
SCLAV_p1072	Serine hydroxymethyltransferase	0.15	-0.22	-0.17	9.32E-01	8.06E-01	8.96E-01	1.11	0.86	0.89
<i>ceaS1</i>	Carboxyethyl arginine synthase 1	1.82	1.18	0.78	6.35E-02	1.72E-01	5.23E-01	3.52	2.27	1.71
<i>bls1</i>	β -Lactam synthetase isoenzyme 1	-0.46	-0.07	-0.47	5.50E-01	9.28E-01	4.53E-01	0.73	0.95	0.72

(Continued on next page)

TABLE 2 (Continued)

Gene cluster and gene	Gene function ^a	M_c^b			BH false-discovery rate-corrected <i>P</i> value			Fold change ^c		
		22.5 h	46.5 h	60 h	22.5 h	46.5 h	60 h	22.5 h	46.5 h	60 h
<i>pah1</i>	Proclavaminate amidinohydrolase	0.00	0.74	-0.45	9.98E-01	3.45E-01	7.12E-01	1.00	1.67	0.73
<i>oat1</i>	Putative glutamate <i>N</i> -acetyltransferase	0.60	0.57	-0.27	8.15E-01	7.02E-01	9.14E-01	1.52	1.48	0.83
<i>cvm6P</i>	PP-dependent aminotransferase-like	0.37	0.39	-0.19	6.51E-01	4.14E-01	8.19E-01	1.29	1.31	0.88
<i>cvm7P</i>	Putative transcriptional regulator	0.21	2.05	0.45	9.14E-01	4.47E-03	6.82E-01	1.16	4.14	1.37
SCLAV_p1080	Two-component system sensor kinase	-0.81	-0.64	-0.43	4.22E-01	3.90E-01	7.03E-01	0.57	0.64	0.74
SCLAV_p1081	Response regulator receiver protein	-0.06	0.32	0.08	9.62E-01	5.09E-01	9.37E-01	0.96	1.25	1.06
SCLAV_p1082	Response regulator-like in TCS	0.60	1.03	0.64	5.50E-01	8.73E-02	4.25E-01	1.52	2.05	1.56
Avg		0.2	0.55	0.01				1.27	1.69	1.06

^aPP, pyridoxal phosphate; TCS, two-component systems.

^bThe transcription values in *S. clavuligerus* ATCC 27064 are taken as 1.0.

^cValues shaded in gray correspond to downregulated genes at the indicated times.

In *S. clavuligerus* Δ oppA2::acc, the increase in the transcription level of the *hlmM* gene, encoding a LuxR-type regulator, was 3.2-fold at the early-exponential phase. In this strain, the average global transcriptional increase of all *hlm* genes at all the sampling times was 2-fold. The highest changes were detected for *hlmK*, encoding a thioesterase (8.3-fold); *hlmH*, encoding a major facilitator superfamily (MFS) transporter (3.7-fold); and *hlmL*, encoding a condensation domain (3.4-fold) (Table 3).

TABLE 3 Effect of the lack of OppA2, the lack of the pSCL4 plasmid, or the lack of both pSCL4 and OppA2 on the transcription of the *hlm* genes for holomycin biosynthesis^a

Mutant	Gene	M_c			BH false-discovery rate-corrected <i>P</i> value			Fold change			Gene function ^b
		22.5 h	46.5 h	60 h	22.5 h	46.5 h	60 h	22.5 h	46.5 h	60 h	
<i>S. clavuligerus</i> Δ oppA2::acc	<i>hlmA</i>	0.93	0.59	0.58	8.1E-01	8.2E-01	8.7E-01	1.90	1.51	1.50	Acyltransferase
	<i>hlmB</i>	1.19	1.54	0.48	6.9E-01	3.5E-01	8.8E-01	2.28	2.92	1.39	Acyl-CoA dehydrogenase
	<i>hlmC</i>	0.72	0.62	0.39	8.5E-01	7.8E-01	9.1E-01	1.64	1.54	1.31	Thioesterase
	<i>hlmD</i>	0.76	0.25	0.58	8.3E-01	9.2E-01	8.5E-01	1.69	1.19	1.49	Oxidoreductase
	<i>hlmE</i>	0.79	0.41	0.63	8.4E-01	8.8E-01	8.5E-01	1.73	1.33	1.54	NRPS
	<i>hlmF</i>	1.34	0.42	0.45	7.5E-01	9.0E-01	9.2E-01	2.52	1.34	1.37	Cys-decarboxylase like
	<i>hlmG</i>	0.56	0.18	0.47	9.0E-01	9.5E-01	8.9E-01	1.48	1.13	1.39	Globin
	<i>hlmH</i>	1.91	0.98	0.53	4.4E-01	6.3E-01	8.8E-01	3.76	1.97	1.45	MFS transporter
	<i>hlmI</i>	1.44	0.83	0.68	6.7E-01	6.9E-01	8.3E-01	2.72	1.78	1.60	Thioredoxin reductase
	<i>hlmK</i>	0.50	1.93	3.07	9.1E-01	2.5E-01	1.3E-01	1.42	3.80	8.35	Thioesterase domain
	<i>hlmL</i>	1.77	0.61	0.37	1.8E-03	2.7E-01	6.7E-01	3.42	1.52	1.29	Condensation domain
<i>hlmM</i>	1.67	0.42	0.15	6.8E-03	5.4E-01	9.1E-01	3.18	1.33	1.11	LuxR-type regulator	
<i>S. clavuligerus</i> pSCL4 ⁻	<i>hlmA</i>	3.60	4.01	2.78	1.27E-02	4.34E-03	3.95E-02	12.13	16.12	6.84	Acyltransferase
	<i>hlmB</i>	2.44	3.01	0.99	6.47E-02	1.62E-02	4.75E-01	5.42	8.03	1.99	Acyl-CoA dehydrogenase
	<i>hlmC</i>	3.72	4.49	2.23	4.72E-03	6.43E-04	6.86E-02	13.19	22.44	4.69	Thioesterase
	<i>hlmD</i>	3.52	4.08	2.30	6.29E-03	1.34E-03	5.47E-02	11.45	16.92	4.92	Oxidoreductase
	<i>hlmE</i>	4.06	4.80	2.99	3.38E-03	5.13E-04	1.89E-02	16.62	27.79	7.94	NRPS
	<i>hlmF</i>	4.33	5.17	3.24	1.06E-02	1.96E-03	4.05E-02	20.15	36.11	9.42	Cys-decarboxylase like
	<i>hlmG</i>	4.23	4.87	3.09	2.63E-03	5.09E-04	1.67E-02	18.77	29.15	8.53	Globin
	<i>hlmH</i>	3.37	5.10	3.87	1.51E-02	3.10E-04	3.21E-03	10.31	34.35	14.64	MFS transporter
	<i>hlmI</i>	3.57	5.46	3.84	8.91E-03	1.22E-04	3.01E-03	11.84	44.08	14.28	Thioredoxin reductase
	<i>hlmK</i>	2.05	2.57	1.16	1.49E-01	4.82E-02	4.11E-01	4.14	5.93	2.24	Thioesterase domain
	<i>hlmL</i>	0.82	1.18	1.26	6.94E-02	6.63E-03	3.00E-03	1.77	2.26	2.40	Condensation domain
<i>hlmM</i>	0.88	1.75	1.25	7.32E-02	3.78E-04	5.98E-03	1.84	3.36	2.38	LuxR-type regulator	
<i>S. clavuligerus</i> Δ oppA2::acc pSCL4 ⁻	<i>hlmA</i>	6.17	3.03	7.06	4.40E-02	7.10E-01	7.80E-02	72.16	8.16	133.56	Acyltransferase
	<i>hlmB</i>	5.14	2.67	4.90	3.40E-02	9.20E-01	7.70E-02	35.30	6.38	29.88	Acyl-CoA dehydrogenase
	<i>hlmC</i>	5.69	3.25	6.10	5.10E-01	5.50E-01	7.80E-02	51.78	9.49	68.76	Thioesterase
	<i>hlmD</i>	5.73	2.92	5.79	4.50E-01	5.80E-01	9.80E-02	53.21	7.56	55.47	Oxidoreductase
	<i>hlmE</i>	6.24	3.30	6.75	4.80E-02	4.60E-01	9.60E-02	75.48	9.86	108.00	NRPS
	<i>hlmF</i>	7.12	3.97	7.53	4.70E-02	6.90E-01	1.30E-01	138.63	15.64	185.17	Cys-decarboxylase like
	<i>hlmG</i>	5.64	3.21	6.10	7.20E-03	4.00E-01	2.40E-01	49.88	9.24	68.39	Globin
	<i>hlmH</i>	4.77	2.89	6.54	7.20E-01	2.00E-01	3.40E-01	27.35	7.39	92.89	MFS transporter
	<i>hlmI</i>	4.49	3.24	7.13	8.60E-01	1.90E-01	1.60E-01	22.47	9.47	140.36	Thioredoxin reductase
	<i>hlmK</i>	3.61	2.23	4.16	6.70E-01	9.30E-03	2.20E-01	12.23	4.71	17.89	Thioesterase domain
	<i>hlmL</i>	1.79	1.29	2.41	3.20E-01	2.30E-03	1.30E-01	3.45	2.44	5.30	Condensation domain
<i>hlmM</i>	1.89	1.16	3.00	3.40E-02	3.90E-01	3.30E-02	3.70	2.24	8.02	LuxR-type regulator	

^aThe *hlmA*-to-*hlmM* genes correspond to SCLAV_5267 to SCLAV_5278 in the StrepDB database. Values for the mutants are given relative to those for *S. clavuligerus* ATCC 27064, taken as 1.0.

^bAcyl-CoA, acyl coenzyme A; NRPS, nonribosomal peptide synthetase; MFS, major facilitator superfamily.

The lack of plasmid pSCL4 resulted in a greater effect on *hlm* gene expression than seen with the *oppA2*-deleted strain (Table 3). In *S. clavuligerus* pSCL4⁻, the average transcriptional level for the 12 *hlm* genes, considering all the sampling times, was 12.6-fold higher than that in the wild-type strain, and *hlmF* and *hlmI* (encoding a cysteine decarboxylase-like protein and a thioredoxin disulfide reductase) were the most affected genes (36- and 44-fold increases, respectively).

A synergistic effect on holomycin biosynthesis was observed for the lack of pSCL4 in an *oppA2*-null background. The expression of *hlmM* increased to 8.2-fold at 60 h, and the average expression of all the genes in *S. clavuligerus* Δ *oppA2::aac* pSCL4⁻, considering all sampling times, was 43-fold, with *hlmF* and *hlmI* transcription expression levels increasing to 185- and 140-fold at 60 h, respectively (Table 3). This additive effect of the lack of OppA2 and plasmid pSCL4 on the transcription of *hlm* genes fits well with the level of holomycin production by strains lacking either pSCL4 or OppA2 and by the double mutant (18) (Fig. S1 in the supplemental material).

Characterization of *S. clavuligerus* Δ *oppA2::acc*[pAV11-*oppA2*], a strain complemented in *oppA2*. All strains lacking OppA2 release the peptide *N*-acetylglycyl-clavaminic acid (AGCA) (14, 15). To confirm that the release of AGCA and the differences on clavulanic acid and holomycin production were due to the lack of OppA2, and not to an indirect effect on the transcription of *orf14*, located downstream of *oppA2*, the *S. clavuligerus* Δ *oppA2::acc* mutant was complemented with plasmid pAV11-*oppA2*. As shown in Fig. 4A, the complemented strain *S. clavuligerus* Δ *oppA2::acc*[pAV11-*oppA2*] restored clavulanic acid production (left panel) to 85% of the level of *S. clavuligerus* ATCC 27064 and reduced holomycin production to levels similar to those of the wild-type strain (right panel). The AGCA peptide was extracted from the broth of the three cultures. High-performance liquid chromatography (HPLC) analysis of imidazole-derivatized AGCA extracts showed the presence of a single peak absorbing at 311 nm, with a retention time (Rt) of 18.3 min, in *S. clavuligerus* Δ *oppA2::acc* extracts (Fig. 4B), as described previously for AGCA (14). The level of AGCA in cultures of *S. clavuligerus* Δ *oppA2::acc*[pAV11-*oppA2*] was reduced to 13% of the level in the noncomplemented strain, and AGCA was almost undetectable in extracts of the wild-type culture broth.

Purification and characterization of AGCA. To confirm that the peak with an Rt of 18.3 min was AGCA, this compound was purified from *S. clavuligerus* Δ *oppA2::aac* broth. The purified compound, when derivatized with imidazole, gave a mass spectrum identical to that published previously (14), with a major fragment of 254 *m/z* (Fig. 4C, left). To avoid interference by imidazole with the interpretation of the fragments, the mass spectrum of underivatized AGCA was obtained (Fig. 4C, right); AGCA showed a major peak of 297.10 *m/z* corresponding to the AGCA molecule, and a fragment of 255.07 *m/z*, which might correspond to the molecule lacking the -COCH₃ group.

Clavulanic acid cosynthesis by nonproducer strains. Clavulanic acid could not be detected in the broth or the mycelium of *S. clavuligerus* Δ *oppA2::aac*. Since the lack of OppA2 prevented CA biosynthesis but did not exert a significant effect on the expression of the clavulanic acid gene cluster, a study was carried out to determine whether the lack of CA production by *S. clavuligerus* Δ *oppA2::aac* was related to the AGCA release reported for *oppA2* mutants (14, 15). To assess whether the AGCA could be used by other CA-negative mutants to produce clavulanic acid, cosynthesis assays were carried out with *S. clavuligerus* Δ *oppA2::aac* and the non-clavulanic acid-producing strains *S. clavuligerus* *pyc::aph*, *S. clavuligerus* RFL35, *S. clavuligerus* *cyp::aph*, *S. clavuligerus* *oppA1::aac*, and *S. clavuligerus* *orf14::aac* (a medium-dependent nonproducer mutant). Solid cosynthesis assays, in which the strains never came in contact, resulted in an almost undetectable inhibition halo, which was observed only in the strip carrying the plates seeded with *S. clavuligerus* Δ *oppA2::aac* and *S. clavuligerus* *pyc::aph* (not shown). Since the diffusion of intermediates in cosynthesis in solid medium might limit the complementation studies, cosynthesis assays were carried out using the liquid medium method, as summarized in Table 4. Clear clavulanic acid formation was already observed at 20 h of growth when *S. clavuligerus* *pyc::aph* or *S. clavuligerus* RFL35 was

TABLE 4 Cosynthesis assays in liquid SA medium^a

Cosynthesis assay ^a	Strain (gene mutated) ^b		Clavulanic acid bioassay result ^c
	Donor	Receptor	
1	<i>S. clavuligerus</i> Δ oppA2::acc (oppA2)	<i>S. clavuligerus</i> pyc::aph (ceaS)	++++
2	<i>S. clavuligerus</i> Δ oppA2::acc (oppA2)	<i>S. clavuligerus</i> RFL35 (bls2)	++++
3	<i>S. clavuligerus</i> Δ oppA2::acc (oppA2)	<i>S. clavuligerus</i> orf14::aph	-----
4	<i>S. clavuligerus</i> Δ oppA2::acc (oppA2)	<i>S. clavuligerus</i> cyp::aph (cyp)	-----
5	<i>S. clavuligerus</i> Δ oppA2::acc (oppA2)	<i>S. clavuligerus</i> oppA1::aph (oppA1)	-----
6	<i>S. clavuligerus</i> cyp::aph (cyp)	<i>S. clavuligerus</i> pyc::aph (ceaS)	-----
7	<i>S. clavuligerus</i> cyp::aph (cyp)	<i>S. clavuligerus</i> RFL35 (bls2)	-----
8	<i>S. clavuligerus</i> pyc::aph (ceaS)	<i>S. clavuligerus</i> Δ oppA2::acc (oppA2)	-----
9	<i>S. clavuligerus</i> RFL35 (bls2)	<i>S. clavuligerus</i> Δ oppA2::acc (oppA2)	-----

^aAssays 1 to 5 were also carried out using mixed cultures of both strains. The complementation results in the bioassay were identical.

^bDonor strains were from spent sterile supernatants; receptor strains were from growing cultures.

^c++++, positive cosynthesis; -----, negative cosynthesis. CA bioassays of each separated strain were always negative. None of the strains shown in this table produces clavulanic acid by itself. All the strains produced cephamycin C.

cocultured with *S. clavuligerus* Δ oppA2::aac (Fig. 5A). CA formation in mixed cultures was maximal at 60 h of growth and reached about 37% of the level produced by the wild-type strain. Conversely, mixed cultures of *S. clavuligerus* Δ oppA2::aac with *S. clavuligerus* cyp::aph, *S. clavuligerus* orf14::aac, or *S. clavuligerus* oppA1::aac did not result in clavulanic acid production (Fig. 5B, assays 6, 8, and 10). The inhibition zone produced by CA in the mixed cultures (Fig. 5B, assays 2 and 4) was clearly different from the small, diffuse inhibition zones due to holomycin (Fig. 5A, assays 6, 8, and 10), an antibiotic produced only by *S. clavuligerus* Δ oppA2::aac, which was very weakly active on *Klebsiella pneumoniae* growth. Mixed cultures of *S. clavuligerus* Δ oppA2::aac with *S. clavuligerus* cyp::aph, *S. clavuligerus* orf14::aac, or *S. clavuligerus* oppA1::aac did not produce clavulanic acid (Fig. 5B, assays 6, 8, and 10).

The bioactivity shown in Fig. 5B (assays 2 and 4) suggested that a metabolite was transferred from a donor strain and converted to clavulanic acid by an acceptor. The donor and acceptor strains in the cosynthesis assays were characterized by interchanging the culture broth between pairs of strains. Spent filter-sterilized broth from *S. clavuligerus* Δ oppA2::aac cultures was added to the mycelium of each of the non-CA-producing strains, and the cultures were kept growing for 24 h. No bioactivity was detected in unsupplemented cultures of any of the strains (Fig. 5C, assays 1, 3, 5, and 7). A clear inhibition zone was observed in supplemented cultures of *S. clavuligerus* pyc::aph and *S. clavuligerus* RFL35 (Fig. 5C, assays 2 and 4) but not in supplemented cultures of *S. clavuligerus* cyp::aph and *S. clavuligerus* orf14::aac (Fig. 5C, assays 6 and 8). The reciprocal assay in which filter-sterilized broth of either *S. clavuligerus* pyc::aph or *S. clavuligerus* RFL35 was added to *S. clavuligerus* Δ oppA2::aac mycelium (not shown) did not result in CA formation, thus confirming that *S. clavuligerus* Δ oppA2::aac was the donor strain and *S. clavuligerus* pyc::aph or *S. clavuligerus* RFL35 was the converter strain.

The intermediate released by the donor strain *S. clavuligerus* Δ oppA2::aac and taken by the converter strains might be AGCA, which is released into the broth by the former strain. Indeed, cultures of *S. clavuligerus* pyc::aph or *S. clavuligerus* RFL35 did not form clavulanic acid when supplemented with the broth of a strain that did not accumulate AGCA, such as *S. clavuligerus* cyp::aph (not shown).

Production of clavulanic acid by cultures supplemented with pure AGCA. To confirm that AGCA was responsible for the CA production, pure AGCA was added at 1 mM to cultures of the different non-CA-producing strains used in this work. AGCA itself did not show bioactivity in the clavulanic acid assay (Fig. 5DIII), nor was the typical yellow color due to holomycin production formed in the cultures (not shown). It can be observed that the wild-type strain produced similar levels of clavulanic acid in the absence of AGCA and after AGCA supplementation (Fig. 5DI and II), indicating that the endogenous supply of this intermediate is not limiting for CA production under the conditions used in this work. CA was not produced by cultures of *S. clavuligerus* Δ oppA2::aac, *S. clavuligerus* cyp::aph, or




FIG 5 Clavulanic acid cosynthesis by nonproducer strains. (A) Liquid culture cosynthesis. Shown is clavulanic acid production by *S. clavuligerus* ATCC 27064 (open circles), *S. clavuligerus* $\Delta oppA2::aac$ (filled circles), *S. clavuligerus* *pyc::aph* (filled triangles), and *S. clavuligerus* RFL35 (open triangles), as well as by cocultures of *S. clavuligerus* *pyc::aph* and *S. clavuligerus* $\Delta oppA2::aac$ (filled squares) and cocultures of *S. clavuligerus* RFL35 and *S. clavuligerus* $\Delta oppA2::aac$ (open squares). (B) Bioassays of the 60-h samples of the pure liquid-medium cultures of the strains used in the assays for which results are shown in panel A (left side) and cocultures of the same strains with *S. clavuligerus* $\Delta oppA2::aac$ (right side). The strains used in the culture are *S. clavuligerus* *pyc::aph* (assays 1 and 2), *S. clavuligerus* RFL35 (assays 3 and 4), *S. clavuligerus* *cyp::aph* (assays 5 and 6), *S. clavuligerus* *orf14::aph* (assays 7 and 8), *S. clavuligerus* *oppA1::aac* (assays 9 and 10), and *S. clavuligerus* ATCC 27064 (assays 11 and 12). Notice the large inhibition zone due to CA formation (assays 2 and 4) and the small diffuse inhibition zones (assays 6, 8, and 10) due to the effect of holomycin on the *Klebsiella*-seeded plates. (C) Cosynthesis by addition of filtered sterile broth of *S. clavuligerus* $\Delta oppA2::aac$. Shown are results of bioassays of the 60-h samples of the pure liquid-medium cultures of strains (left side) and the effects of adding 50 ml of the filtered sterile spent broth of an *S. clavuligerus* $\Delta oppA2::aac$ culture (right side). The strains used are *S. clavuligerus* *pyc::aph* (assays 1 and 2), *S. clavuligerus* RFL35 (assays 3 and 4), *S. clavuligerus* *cyp::aph* (assays 5 and 6), *S. clavuligerus* *orf14::aph* (assays 7 and 8), and *S. clavuligerus* ATCC 27064 (assays 11 and 12). (D) Clavulanic acid production by cultures supplemented with pure AGCA. (I) Unsupplemented cultures; (II) cultures supplemented with AGCA (1 mM); (III) pure AGCA (1 mM). The strains used were *S. clavuligerus* ATCC 27064 (WT), *S. clavuligerus* $\Delta oppA2::aac$ (*oppA2*), *S. clavuligerus* *orf14::aph* (*orf14*), *S. clavuligerus* *cyp::aph* (*cyp*), *S. clavuligerus* RFL35 (β -*Is*), and *S. clavuligerus* *pyc::aph* (*pyc*).

S. clavuligerus *orf14::aac* (Fig. 5DII). However, *S. clavuligerus* *pyc::aph* and *S. clavuligerus* RFL35 cultures recovered the ability to produce clavulanic acid after AGCA supplementation (5DII) and produced about 40% of the CA produced by the parental strain, confirming that these two early-blocked mutants still have the enzymes for the conversion of AGCA into clavulanic acid.

DISCUSSION

OppA periplasmic proteins are important in chemotaxis and virulence due to their substrate-binding and transport abilities as part of ABC systems (23, 28). In addition, ecto-ATPase activity (29) or chaperone-like functions in protein folding (30) have been described for these proteins.

Hitherto, the role of OppA2, essential for clavulanic acid biosynthesis, has been unclear. In this study, additional information about this oligopeptide permease has been obtained through transcriptomic analysis, cosynthesis assays, and complementation studies.

The expression of 233 genes was significantly affected by the lack of OppA2. The holomycin gene cluster (*hlm*) was overexpressed, whereas the expression levels of clavulanic acid, cephamycin C, and clavam gene clusters were not affected. The high expression levels of the *hlm* genes in *S. clavuligerus* $\Delta oppA2::aac$, which lacks OppA2 but has standard copy numbers of plasmids pSCL1, pSCL2 and pSCL4, are independent of the effect of the lack of the megaplasmid pSCL4, as shown in *S. clavuligerus* pSCL4⁻ and described previously (18). This suggests two different mechanisms of *hlm* gene cluster activation. The upregulation of the *hlmC*, *hlmE*, and *hlmF* genes, encoding biosynthetic enzymes, and of *hlmH*, coding for an MFS transporter, probably responds to the overexpression of the LuxR-type regulator encoded by *hlmM*. But the expression of *hlmM* itself might be controlled by other negative regulators. The overproduction of proteases and peptidases in the *oppA2* mutant (Table 1) might trigger a proteolysis activity which inactivates negative regulators controlling the holomycin gene cluster, thus releasing holomycin formation. A similar phenomenon generates morphological and physiological differentiation in *S. coelicolor* in response to alterations in the synthesis of the ATP-dependent protease Clp (31).

The *oppA2* transcript dropped to background levels in the *oppA2* mutant, but the expression of other clavulanic acid biosynthesis genes remained unaffected; therefore, the lack of the OppA2 protein itself must be responsible for the CA-null production. The CA pathway in the *oppA2* mutant must be functional up to the formation of *N*-glycyl-clavaminic acid (NGCA), by condensation of glycine and clavaminic acid (Fig. 1), since all the genes involved (*ceaS2* to *gcaS*) are transcribed. The *N*-glycyl-clavaminic acid synthetase (*GcaS*) does not use *N*-acetyl-glycine as a cosubstrate (32) to form *N*-acetyl-glycylclavaminic acid (AGCA); therefore, the AGCA molecule must be generated by acetylation of NGCA (32). The protein encoded by *orf14* (SCLAV_4185) is a member of the GCN5-related *N*-acetyltransferases (GNAT) and carries NAT domains; however, it should act downstream of AGCA formation, since the addition of pure AGCA to the *orf14* mutant does not result in clavulanic acid cosynthesis.

AGCA is structurally similar to *N*-acetyl-glycyl-arginine, one of the arginine-derived peptides that has been reported to be bound by OppA2 (17). Thus, OppA2 might bind AGCA, carry it to the correct position in the cell, and translocate it to the next enzyme of the pathway, which is determining for the proper conversion of AGCA to clavulanic acid. In the absence of OppA2, the AGCA peptide is released to the medium (14, 15). The positive cosynthesis by *S. clavuligerus* $\Delta oppA2::aac$ and either *S. clavuligerus* *pyc::aph* or *S. clavuligerus* RFL35, in which these mutants blocked in the early steps of the pathway act as converters (receptors), indicates that the AGCA released by *S. clavuligerus* $\Delta oppA2::aac$ (the donor strain) can be bound and correctly located by the OppA2 protein of the receptor strain and then is processed by the enzymes of the late steps of the pathway, which are functional in the two converting receptor strains, to form clavulanic acid (Fig. 6). The CA-null mutants *S. clavuligerus* *cyp::aph*, *S. clavuligerus* *orf14::aac*, and *S. clavuligerus* *oppA1::aac* are unable to form clavulanic acid from AGCA, suggesting that the steps involving the formation of CA from AGCA are affected in these mutants.

To proceed to form CA, the *N*-acetyl-glycyl group from AGCA must be released by an oxidative deamination in enzymatic steps that are still obscure. The final step of the pathway is the reduction of the C-5 aldehyde group of clavaldehyde by the clavaldehyde reductase (33) to produce clavulanic acid.

In summary, the existing evidence suggests that clavulanic acid is formed through a modified peptide intermediate, AGCA. This peptide is bound by the OppA2 protein and is probably delivered to a membrane-bound complex formed by the late enzymes of the biosynthetic pathway with the final formation and secretion of clavulanic acid. When pure AGCA, or AGCA present in the broth of the *oppA2* mutant, is added to




FIG 6 Scheme for clavulanic acid biosynthesis. The model explains the performance of the donor strain, *S. clavuligerus* $\Delta oppA2::aac$, on the right and the performance of the receptor strains, *S. clavuligerus* *pyc::aph* (with *ceaS2* disrupted) and *S. clavuligerus* RFL35 (with *bls2* deleted), on the left. The compound transferred in the cosynthesis and the pathway for clavulanic acid formation are shown. Notice the presence of a functional OppA2 protein in each of the receptor strains.

cultures of a receptor strain, the functional OppA2 protein of this converter strain binds AGCA from the medium and proceeds with the formation of clavulanic acid.

MATERIALS AND METHODS

Strains and culture conditions. The wild-type strain *S. clavuligerus* ATCC 27064 was used as the control and parental strain. *S. clavuligerus* $\Delta oppA2::aac$ is an *oppA2* deletion strain in which the *oppA2* gene is replaced by an apramycin resistance cassette; *S. clavuligerus* pSCL4⁻ carries the wild-type *oppA2* gene but lacks the pSCL4 plasmid; *S. clavuligerus* $\Delta oppA2::aac$ pSCL4⁻ is a double mutant in which the *oppA2* gene is replaced by an apramycin resistance cassette and the pSCL4 plasmid is lacking. The origin and characteristics of the *Streptomyces* strains used in this work are shown in Table 5.

The strains were grown at 28°C and 220 rpm in 100 ml of tryptic soy broth (TSB) medium to an optical density at 600 nm (OD₆₀₀) of 5 to 8. A volume of 5 ml was taken, and the mycelium was washed with a 0.9% NaCl solution and was used to inoculate 500-ml baffled flasks containing 100 ml of starch-asparagine (SA) medium (34); the cultures were incubated during growth at the same temperature with shaking. Growth was estimated by measuring the DNA concentration using the diphenylamine assay (35).

In AGCA-feeding experiments, the strains were grown in TSB medium for 24 h. These cultures were used to inoculate 25-ml flasks containing 5 ml of SA medium with an initial OD₆₀₀ of 0.25. After 36 h, AGCA was added to a final concentration of 1 mM. Samples for clavulanic acid bioassays were taken at 60 h of culture.

Complementation of the *oppA2* deletion. A DNA fragment (2,063 bp) containing the *oppA2* gene with its promoter was amplified by PCR using primers CP-*oppA2*D (ACCGACACCGATCAGAAGAG) and CP-*oppA2*R (CACCACAGCAGTGCCAGTC), sequenced, and cloned into the EcoRV site of the conjugative-integrative plasmid pAV11 to produce pAV11-*oppA2*. The EcoRV site is located downstream of the anhydrotetracycline-inducible promoter *tcp-830*. Plasmid pAV11-*oppA2* was introduced into *S. clavuligerus* $\Delta oppA2::aac$ by *Escherichia coli* conjugation, and the complemented strain *S. clavuligerus* $\Delta oppA2::aac$ [pAV11-*oppA2*] was selected by apramycin and hygromycin resistance. As a control, the *S. clavuligerus* $\Delta oppA2::aac$ [pAV11] strain, lacking the *oppA2* gene, was constructed. The presence of *oppA2* in the

TABLE 5 Characteristics of the *Streptomyces* strains used in this work

Strain	Characteristic(s)	Plasmid content	Origin or reference(s)
<i>S. clavuligerus</i> ATCC 27064	Control strain	Standard copy no. of pSCL1, pSCL2, pSCL4	ATCC
<i>S. clavuligerus</i> $\Delta oppA2::acc$	<i>oppA2</i> deleted; apramycin resistant; previously named <i>S. clavuligerus</i> $\Delta oppA2::acc$ pSCL4 ⁺	Standard copy no. of pSCL1, pSCL2, pSCL4	18
<i>S. clavuligerus</i> pSCL4 ⁻	Lacking plasmid pSCL4	Lacking plasmid pSCL4; standard copy no. of pSCL1 and pSCL2	18
<i>S. clavuligerus</i> $\Delta oppA2::acc$ pSCL4 ⁻	<i>oppA2</i> deleted; apramycin resistant; lacking plasmid pSCL4	Lacking plasmid pSCL4; standard copy no. of pSCL1 and pSCL2	18
<i>S. clavuligerus</i> $\Delta oppA2::acc$ [pAV11- <i>oppA2</i>]	<i>oppA2</i> inserted in plasmid pAV11 to complement the <i>oppA2</i> -deletion in the parental strain; apramycin and hygromycin resistant	Standard copy no. of pSCL1, pSCL2, pSCL4	This work
<i>S. clavuligerus</i> $\Delta oppA2::acc$ [pAV11]	<i>oppA2</i> deleted; apramycin, thiostrepton resistant	Standard copy no. of pSCL1, pSCL2, pSCL4	This work
<i>S. clavuligerus</i> <i>pyc::aph</i>	<i>ceaS2</i> disrupted; kanamycin resistant	Standard copy no. of pSCL1, pSCL2, pSCL4	11, 36
<i>S. clavuligerus</i> RFL35	<i>bIS2</i> deleted; thiostrepton resistant	Standard copy no. of pSCL1, pSCL2, pSCL4	43
<i>S. clavuligerus</i> <i>cyp::aph</i>	<i>cyp</i> disrupted; kanamycin resistant	Standard copy no. of pSCL1, pSCL2, pSCL4	25
<i>S. clavuligerus</i> <i>orf14::aph</i>	<i>orf14</i> disrupted; kanamycin resistant	Standard copy no. of pSCL1, pSCL2, pSCL4	25
<i>S. clavuligerus</i> <i>oppA1::aac</i>	<i>oppA1</i> disrupted; apramycin resistant	Standard copy no. of pSCL1, pSCL2, pSCL4	15

complemented strain was confirmed by PCR and sequencing of the amplicon. When required, the complemented strains were grown in the presence of anhydrotetracycline (10 μ g/ml).

Antibiotic production. Antibiotics were assayed from culture supernatants. The clavulanic acid concentration was quantified using *Klebsiella pneumoniae* ATCC 29665 as described previously (11, 36). Controls without penicillin G in the bioassay were always carried out to confirm that the inhibition zone was due to clavulanic acid. Holomycin was quantified by bioassays using *Micrococcus luteus* ATCC 9341 or by HPLC as described by de la Fuente et al. (37). Cephamycin C was tested by bioassays using *Escherichia coli* Ess22-31, which is supersensitive to β -lactam antibiotics (38).

Purification and characterization of AGCA. *Streptomyces clavuligerus* $\Delta oppA2::acc$ was grown in SA medium for 48 h as described above. The collected broth (total volume, 1,000 ml) was filtered and concentrated to a final volume of 5 ml. The concentrated broth (100 μ l) was analyzed by preparative HPLC using a SunFire C₁₈ column (10 μ m; 10 by 150 mm; Waters). As the mobile phase, acetonitrile (A) and water containing 0.05% trifluoroacetic acid (TFA) (B) were used under isocratic conditions, 35% A and 65% B, with a flow rate of 5 ml/min. The location of the sample containing AGCA (Rt, 4.5 min) was determined by collecting samples every 0.5 min, derivatizing them with imidazole (39), and then performing HPLC analysis (Rt of imidazole-derivatized AGCA, 18.3 min) and mass spectrometry as described previously (14). Samples were collected from 50 HPLC runs and were lyophilized to obtain 11.8 mg of pure AGCA.

HPLC-MS analyses were done in an Alliance chromatographic system coupled to a ZQ4000 mass spectrometer using an Atlantis T3 column (3 μ m; 2.1 by 150 mm; Waters, Milford, MA). Samples (10 μ l) were injected and were eluted with 0.1% formic acid in water for 4 min, followed by a linear gradient from 0 to 40% acetonitrile over 16 min at 0.2 ml/min. MS analyses of the underivatized AGCA were carried out by electrospray ionization in negative mode, with a capillary voltage of 3 kV and a cone voltage of 10 V. AGCA was detected by selected ion recording at *m/z* 297.

Cosynthesis studies. To study clavulanic acid formation by cosynthesis between *S. clavuligerus* $\Delta oppA2::acc$ and other non-clavulanic acid-producing mutants, two types of experiments were done. First, for solid-medium cosynthesis, the tested strains were grown in close physical proximity, but not in contact, on SA plates for 36 and 48 h. Clavulanic acid formation was detected by a bioassay of a 5-cm strip of the solid culture carrying the ends of each strain culture and the empty central space. Control strips carrying each of the tested strains separately were included in the bioassay. Second, for liquid-medium cosynthesis, *S. clavuligerus* $\Delta oppA2::acc$ (A) and the strain to be studied for cosynthesis (B) were grown separately in 100 ml of TSB medium as described above. The mycelia were washed with 0.9% NaCl, and 2.5% (vol/vol) of each strain mycelium was used to jointly inoculate 500-ml baffled flasks containing 100 ml of SA medium. The mixed cultures were grown for 60 h.

To determine the donor and converter strains in clavulanic acid cosynthesis experiments, *S. clavuligerus* $\Delta oppA2::acc$ (A) and the strain to be studied (B) were grown separately in 100 ml of SA medium for 36 h as described above. From each culture, 50 ml was filtered under sterile conditions through a 0.45- μ m-pore-diameter filter; then the filtered spent broth of strain A was added to the culture of strain B, and vice versa, keeping a final 100-ml volume for each culture. The strains were allowed to grow for an additional 24 h. As a control, separated cultures (strains A and B) were used, in which no interchange of the supernatant was performed.

RNA extraction and purification. RNA was extracted from samples taken at the early-exponential, exponential, and stationary phases of growth (22.5, 46.5, and 60 h). An additional sample of the wild-type strain was taken at 36 h. For RNA isolation, samples from *S. clavuligerus* ATCC 27064, *S. clavuligerus* $\Delta oppA2::acc$, *S. clavuligerus* $\Delta oppA2::acc$ pSCL4⁻, and *S. clavuligerus* pSCL4⁻ cultures in SA medium were

taken at 22.5 h, 46.5 h, and 60 h and were stabilized with 2 volumes of RNAprotect Bacteria reagent (Qiagen) for 5 min, and finally 150 μ l lysozyme (30 mg/ml) in Tris-EDTA (TE) buffer was added to the stabilized mycelium pellet of 1 ml of culture samples. After 10 min, 600 μ l buffer RLT (Qiagen) with β -mercaptoethanol was added to the samples, which were then mixed by vortexing, transferred to Lysing Matrix B (MP Biomedicals) microtubes, and processed in a FastPrep instrument (MP Biomedicals) with the following program: 30 s at 6.5 m/s; 1 min at 0°C; 30 s at 6.5 m/s; 1 min at 0°C. One volume of phenol-chloroform-isoamyl alcohol was added to the extracts, and the aqueous phase was applied to RNeasy minikit columns (Qiagen) according to the manufacturer's instructions. RNA preparations were incubated with DNase I (Qiagen) to eliminate DNA contamination. The RNA was spectrophotometrically quantified in a NanoDrop ND-1000 UV-Vis spectrophotometer (Thermo Scientific), and its integrity was determined using a Bioanalyzer 2100 instrument and the RNA 6000 Nano LabChip kit (Agilent Technologies). Only RNAs with RNA integrity values above 7.0 were used.

Microarray procedures. Agilent microarrays with a format of 8 \times 15K were designed previously (40) to target a total of 7,589 *S. clavuligerus* loci, including 5,710 chromosomal and 1,581 pSCL4-coding sequences. Nucleic acid labeling, hybridization and washing conditions, image scanning, and statistical analysis were performed as described previously (40). Briefly, RNA preparations were labeled with Cy3-dCTP and were hybridized altogether with Cy5-labeled genomic DNA (gDNA), used as the common reference; fluorescence signals were detected with an Agilent G2565BA scanner and were quantified with Feature Extraction software (Agilent), and the signal values normalized and processed with the limma package (41) in the R environment (42). The M_g value, the normalized binary log of Cy3/Cy5 net intensities, is proportional to the abundance of the transcript for a particular gene (40). The M_g transcription values (GSE data sets) of the six experimental conditions were compared using three contrasts, mutant versus wild type, corresponding to the three growth times studied. For each gene and comparison, P values and M_c values were calculated from biological duplicates. M_c values are binary log values of the differential transcription between the mutant and the wild-type strain (positive and negative values indicate upregulation and downregulation, respectively). The Benjamini-Hochberg (BH) false-discovery rate adjustment was applied to the P values, so a result was considered statistically significant when the BH-corrected P value was < 0.05 .

Accession number(s). The microarray data used in this work have been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus database under accession numbers GSE66683, GSE92399, and GSE99917.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/AEM.01701-18>.

SUPPLEMENTAL FILE 1, PDF file, 0.4 MB.

ACKNOWLEDGMENTS

This work was supported by grant BIO2013-34723 from the Spanish Ministry of Economy and Competitiveness. R. Álvarez-Álvarez and Y. Martínez-Burgo received a PFU fellowship from the Spanish Ministry of Science and Innovation.

We appreciate the gift of the *S. clavuligerus* RFL35 strain from C. A. Townsend. The advice of R. Pérez-Redondo in initial experiments is appreciated.

P.L., J.F.M., and R.Á.-Á. conceived and designed the research. R.Á.-Á. and Y.M.-B. performed the research. A.R.-G. performed bioinformatic studies. P.L. wrote the manuscript.

We declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

REFERENCES

- Pearce SR, Mimmack ML, Gallagher MP, Gileadi U, Hyde SC, Higgins CF. 1992. Membrane topology of the integral membrane components, OppB and OppC, of the oligopeptide permease of *Salmonella typhimurium*. *Mol Microbiol* 6:47–57. <https://doi.org/10.1111/j.1365-2958.1992.tb00836.x>.
- Monnet V. 2003. Bacterial oligopeptide-binding proteins. *Cell Mol Life Sci* 60:2100–2114. <https://doi.org/10.1007/s00018-003-3054-3>.
- Goodell EW, Higgins CF. 1987. Uptake of cell wall peptides by *Salmonella typhimurium* and *Escherichia coli*. *J Bacteriol* 169:3861–3865. <https://doi.org/10.1128/jb.169.8.3861-3865.1987>.
- Perego M, Higgins CF, Pearce SR, Gallagher MP, Hoch JA. 1991. The oligopeptide transport system of *Bacillus subtilis* plays a role in the initiation of sporulation. *Mol Microbiol* 5:173–185. <https://doi.org/10.1111/j.1365-2958.1991.tb01838.x>.
- Nodwell JR, McGovern K, Losick R. 1996. An oligopeptide permease responsible for the import of an extracellular signal governing aerial mycelium formation in *Streptomyces coelicolor*. *Mol Microbiol* 22: 881–893. <https://doi.org/10.1046/j.1365-2958.1996.01540.x>.
- Nodwell JR, Losick R. 1998. Purification of an extracellular signaling molecule involved in production of aerial mycelium by *Streptomyces coelicolor*. *J Bacteriol* 180:1334–1337.
- Keijsers BJ, van Wezel GP, Canters GW, Vliegenhart EJ. 2002. Developmental regulation of the *Streptomyces lividans ram* genes: involvement of RamR in regulation of the *ramCSAB* operon. *J Bacteriol* 184: 4420–4429. <https://doi.org/10.1128/JB.184.16.4420-4429.2002>.
- O'Connor TJ, Nodwell JR. 2005. Pivotal roles for the receiver domain in the mechanism of action of the response regulator RamR of *Streptomyces coelicolor*. *J Mol Biol* 351:1030–1047. <https://doi.org/10.1016/j.jmb.2005.06.053>.
- Akanuma G, Ueki M, Ishizuka M, Ohnishi Y, Horinouchi S. 2011. Control

- of aerial mycelium formation by the BldK oligopeptide ABC transporter in *Streptomyces griseus*. FEMS Microbiol Lett 315:54–62. <https://doi.org/10.1111/j.1574-6968.2010.02177.x>.
10. Hiles ID, Gallagher MP, Jamieson DJ, Higgins CF. 1987. Molecular characterization of the oligopeptide permease of *Salmonella typhimurium*. J Mol Biol 195:125–142. [https://doi.org/10.1016/0022-2836\(87\)90332-9](https://doi.org/10.1016/0022-2836(87)90332-9).
 11. Pérez-Redondo R, Rodríguez-García A, Martín JF, Liras P. 1999. Deletion of the *pyc* gene blocks clavulanic acid biosynthesis except in glycerol-containing medium: evidence for two different genes in formation of the C3 unit. J Bacteriol 181:6922–6928.
 12. Liras P, Santamarta I, Pérez-Redondo R. 2010. Clavulanic acid and clavams biosynthesis and regulation, p 167–178. In Dyson P (ed), *Streptomyces: molecular biology and biotechnology*. Horizon Press, Norwich, United Kingdom.
 13. Mellado E, Lorenzana LM, Rodríguez-Sáiz M, Díez B, Liras P, Barredo JL. 2002. The clavulanic acid biosynthetic cluster of *Streptomyces clavuligerus*: genetic organization of the region upstream of the *car* gene. Microbiology 148:1427–1438. <https://doi.org/10.1099/00221287-148-5-1427>.
 14. Jensen SE, Paradkar AS, Mosher RH, Anders C, Beatty PH, Brumlik MJ, Griffin A, Barton B. 2004. Five additional genes are involved in clavulanic acid biosynthesis in *Streptomyces clavuligerus*. Antimicrob Agents Chemother 48:192–202. <https://doi.org/10.1128/AAC.48.1.192-202.2004>.
 15. Lorenzana LM, Pérez-Redondo R, Santamarta I, Martín JF, Liras P. 2004. Two oligopeptide-permease-encoding genes in the clavulanic acid cluster of *Streptomyces clavuligerus* are essential for production of the β -lactamase inhibitor. J Bacteriol 186:3431–3438. <https://doi.org/10.1128/JB.186.11.3431-3438.2004>.
 16. Tame JR, Dodson EJ, Murshudov G, Higgins CF, Wilkinson AJ. 1995. The crystal structures of the oligopeptide-binding protein OppA complexed with tripeptide and tetrapeptide ligands. Structure 3:1395–1406. [https://doi.org/10.1016/S0969-2126\(01\)00276-3](https://doi.org/10.1016/S0969-2126(01)00276-3).
 17. Mackenzie AK, Valegård K, Iqbal A, Caines MEC, Kershaw NJ, Jensen SE, Schofield CJ, Andersson I. 2010. Crystal structures of an oligopeptide-binding protein from the biosynthetic pathway of the β -lactamase inhibitor clavulanic acid. J Mol Biol 396:332–344. <https://doi.org/10.1016/j.jmb.2009.11.045>.
 18. Álvarez-Álvarez R, Rodríguez-García A, Martínez-Burgo Y, Robles-Reglero V, Santamarta I, Pérez-Redondo R, Martín JF, Liras P. 2014. A 1.8-Mb-reduced *Streptomyces clavuligerus* genome: relevance for secondary metabolism and differentiation. Appl Microbiol Biotechnol 98:2183–2195. <https://doi.org/10.1007/s00253-013-5382-z>.
 19. Medema MH, Trefzer A, Kovalchuk A, van den Berg M, Müller U, Heijne W, Wu L, Alam MT, Ronning CM, Niernan WC, Bovenberg RA, Breitling R, Takano E. 2010. The sequence of a 1.8-Mb bacterial linear plasmid reveals a rich evolutionary reservoir of secondary metabolic pathways. Genome Biol Evol 2:212–224. <https://doi.org/10.1093/gbe/evq013>.
 20. Li B, Walsh CT. 2010. Identification of the gene cluster for the dithiolopyrrolone antibiotic holomycin in *Streptomyces clavuligerus*. Proc Natl Acad Sci U S A 107:19731–19735. <https://doi.org/10.1073/pnas.1014140107>.
 21. Liras P. 2014. Holomycin, a dithiolopyrrolone compound produced by *Streptomyces clavuligerus*. Appl Microbiol Biotechnol 98:1023–1030. <https://doi.org/10.1007/s00253-013-5410-z>.
 22. Álvarez-Álvarez R, Martínez-Burgo Y, Pérez-Redondo R, Braña AF, Martín JF, Liras P. 2013. Expression of the endogenous and heterologous clavulanic acid cluster in *Streptomyces flavogriseus*: why a silent cluster is sleeping. Appl Microbiol Biotechnol 97:9451–9463. <https://doi.org/10.1007/s00253-013-5148-7>.
 23. Sievers S, Lund A, Menéndez-Gil P, Nielsen A, Møllerup MS, Nielsen SL, Larsson PB, Borch-Jensen J, Johansson J, Kallipolitis BH. 2015. The multicopy sRNA LhrC controls expression of the oligopeptide-binding protein OppA in *Listeria monocytogenes*. RNA Biol 12:985–997. <https://doi.org/10.1080/15476286.2015.1071011>.
 24. Santamarta I, López-García MT, Kurt A, Nárdiz N, Álvarez-Álvarez R, Pérez-Redondo R, Martín JF, Liras P. 2011. Characterization of DNA-binding sequences for CcaR in the cephamycin-clavulanic acid supercluster of *Streptomyces clavuligerus*. Mol Microbiol 81:968–981. <https://doi.org/10.1111/j.1365-2958.2011.07743.x>.
 25. Lorenzana LM. 2003. Agrupación de genes de biosíntesis de ácido clavulánico en *Streptomyces clavuligerus*. Análisis de la región corriente arriba del gen *car*. PhD thesis, Universidad de León, León, Spain.
 26. Charusanti P, Fong NI, Nagarajan H, Pereira AR, Li HJ, Abate EA, Su Y, Gerwick WH, Palsson BO. 2012. Exploiting adaptive laboratory evolution of *Streptomyces clavuligerus* for antibiotic discovery and overproduction. PLoS One 7:e33727. <https://doi.org/10.1371/journal.pone.0033727>.
 27. Robles-Reglero V, Santamarta I, Álvarez-Álvarez R, Martín JF, Liras P. 2013. Transcriptional analysis and proteomics of the holomycin gene cluster in overproducer mutants of *Streptomyces clavuligerus*. J Biotechnol 163:69–76. <https://doi.org/10.1016/j.jbiotec.2012.09.017>.
 28. Dasgupta A, Sureka K, Mitra D, Saha B, Sanyal S, Das AK, Chakrabarti P, Jackson M, Gicquel B, Kundu M, Basu J. 2010. An oligopeptide transporter of *Mycobacterium tuberculosis* regulates cytokine release and apoptosis of infected macrophages. PLoS One 58:e12225. <https://doi.org/10.1371/journal.pone.0012225>.
 29. Hopfe M, Henrich B. 2004. OppA, the substrate-binding subunit of the oligopeptide permease, is the major ecto-ATPase of *Mycoplasma hominis*. J Bacteriol 186:1021–1028. <https://doi.org/10.1128/JB.186.4.1021-1028.2004>.
 30. Richarme G, Caldas TD. 1997. Chaperone properties of the bacterial periplasmic substrate-binding proteins. J Biol Chem 272:15607–15612. <https://doi.org/10.1074/jbc.272.25.15607>.
 31. de Crécy-Lagard V, Servant-Moisson P, Viala J, Grandvalet C, Mazodier P. 1999. Alteration of the synthesis of the Clp ATP-dependent protease affects morphological and physiological differentiation in *Streptomyces*. Mol Microbiol 32:505–517. <https://doi.org/10.1046/j.1365-2958.1999.01364.x>.
 32. Arulanantham H, Kershaw NJ, Hewitson KS, Hughes CE, Thirkettle JE. 2006. ORF17 from the clavulanic acid biosynthesis gene cluster catalyzes the ATP-dependent formation of *N*-glycyl-clavaminic acid. J Biol Chem 281:279–287. <https://doi.org/10.1074/jbc.M507711200>.
 33. Nicholson NH, Baggaley KH, Cassels R, Davison M, Elson SW, Fulston M, Tyler JW, Woroniecki SR. 1994. Evidence that the immediate biosynthetic precursor of clavulanic acid is its *N*-aldehyde analogue. J Chem Soc Chem Commun (Camb) 1994:1281–1282. <https://doi.org/10.1039/c39940001281>.
 34. Aidoo KA, Wong A, Alexander DC, Rittammer RA, Jensen SE. 1994. Cloning, sequencing and disruption of a gene from *Streptomyces clavuligerus* involved in clavulanic acid biosynthesis. Gene 147:41–46. [https://doi.org/10.1016/0378-1119\(94\)90036-1](https://doi.org/10.1016/0378-1119(94)90036-1).
 35. Burton K. 1956. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62:315–323. <https://doi.org/10.1042/bj0620315>.
 36. Pérez-Redondo R. 2000. Genética de la producción de ácido clavulánico en *Streptomyces clavuligerus*. PhD thesis, Universidad de León, León, Spain.
 37. de la Fuente A, Lorenzana LM, Martín JF, Liras P. 2002. Mutants of *Streptomyces clavuligerus* with disruptions in different genes for clavulanic acid biosynthesis produce large amounts of holomycin: possible cross-regulation of two unrelated secondary metabolic pathways. J Bacteriol 184:6559–6565. <https://doi.org/10.1128/JB.184.23.6559-6565.2002>.
 38. Hu WS, Braña AF, Demain AL. 1984. Carbon source regulation of cephem antibiotic production by resting cells of *Streptomyces clavuligerus* and its reversal by protein synthesis inhibitors. Enzyme Microb Technol 6:155–160. [https://doi.org/10.1016/0141-0229\(84\)90023-1](https://doi.org/10.1016/0141-0229(84)90023-1).
 39. Foulstone M, Reading C. 1982. Assay of amoxicillin and clavulanic acid, the components of augmentin, in biological fluids with high-performance liquid chromatography. Antimicrob Agents Chemother 22:753–762. <https://doi.org/10.1128/AAC.22.5.753>.
 40. Martínez-Burgo Y, Álvarez-Álvarez R, Rodríguez-García A, Liras P. 2015. The pathway-specific regulator ClrA of *Streptomyces clavuligerus* has a global effect on the expression of genes for secondary metabolism and differentiation. Appl Environ Microbiol 81:6637–6648. <https://doi.org/10.1128/AEM.00916-15>.
 41. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. 2015. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 437:e47. <https://doi.org/10.1093/nar/gkv007>.
 42. R Core Team. 2014. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. <https://www.r-project.org/>.
 43. Bachmann BO, Rongfeng L, Townsend CA. 1998. β -Lactam synthetase: a new biosynthetic enzyme. Proc Natl Acad Sci U S A 95:9082–9086.